At a glance
- Originator Shionogi
- Class Antifungals; Antineoplastics; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Immunosuppression
Most Recent Events
- 30 Jun 1998 Discontinued-Preclinical for Cancer in Japan (Unknown route)
- 30 Jun 1998 Discontinued-Preclinical for Immunosuppression in Japan (Unknown route)
- 19 Dec 1995 Preclinical development for Cancer in Japan (Unknown route)